首页>
外国专利>
Pharmaceutical formulation for subcutaneous intramuscular or intradermal administration use of it and a derivative of extinction of a recombinant factor VIII and process for the treatment of hemophilia
Pharmaceutical formulation for subcutaneous intramuscular or intradermal administration use of it and a derivative of extinction of a recombinant factor VIII and process for the treatment of hemophilia
展开▼
机译:皮下肌内或皮内给药的药物制剂及其重组VIII因子的灭绝衍生物的用途和治疗血友病的方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
PCT No. PCT/SE95/00348 Sec. 371 Date Sep. 17, 1996 Sec. 102(e) Date Sep. 17, 1996 PCT Filed Mar. 31, 1995 PCT Pub. No. WO95/26750 PCT Pub. Date Oct. 12, 1995The present invention relates to a pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration comprising coagulation factor VIII or factor IX and use thereof for manufacture of a medicament for treating haemophilia A or B. The formulation comprises coagulation factor VIII or factor IX with an activity of at least 200 IU/ml and an additive increasing the bio-availability of factor VIII or factor IX. Tests with factor VIII gives a therapeutic level of active factor VIII in the blood stream for a surprisingly long period of time after subcutaneous, intramuscular or intradermal administration. The factor VIII is suitably a highly purified recombinant factor VII, and preferably a deletion derivative thereof, which can be used for the manufacture of a medicament for subcutaneous administration.
展开▼